A snapshot of microarray-generated gene expression signatures associated with ovarian carcinoma

International Journal of Gynecological Cancer

Volumn 18, Issue 6, 2008, Pages 1215-1233

  Gyorffy B ^a,b   Dietel, M ^a   Fekete, T ^b   Lage, H ^a  

^a Charité Campus Benjamin Franklin Medical Center   (Germany)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Gene expression; Microarrays; Ovarian cancer; Transcriptomics

Indexed keywords

ARTICLE; CANCER GROWTH; CANCER RESEARCH; CARCINOGENESIS; DNA MICROARRAY; GENE CONTROL; GENE EXPRESSION; GENE IDENTIFICATION; HISTOLOGY; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS;

CELL DIFFERENTIATION; COMPUTER SIMULATION; DATABASES, NUCLEIC ACID; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME;

EID: 55949116984     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.01169.x     Document Type: Article

References (80)

1. Steward BW, Kleihues P. World Cancer Report. Lyon, France : IARC Press, 2003.
2. Kaku T, Ogawa S, Kawano Y et al. Histological classification of ovarian cancer. Med Electron Microsc 2003 36 : 9 17.
3. Ozols RF, Schwartz PE, Eifel PJ. Ovarian cancer, fallopian tube carcinoma and peritoneal carcinoma. In : Devita VT, Hellman S, Rosenburg SA, eds. Cancer, principles and practice of oncology, 6th edn. Philadelphia, PA : Lippincott Williams & Wilkins, 2001 : 1597 632.
4. DiSaia PJ, Bloss JD. Treatment of ovarian cancer: new strategies. Gynecol Oncol 2003 90 : S24 32.
5. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003 3 : 502 16.
6. Mutch DG. Surgical management of ovarian cancer. Semin Oncol 2002 29 : 3 8.
7. Ozols RF. Future directions in the treatment of ovarian cancer. Semin Oncol 2002 29 (Suppl. 1 32 42.
8. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000 19 : 3 10.
9. Aunoble B, Sanches R, Didier E, Bignon YJ. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer. Int J Oncol 2000 16 : 567 76.
10. Ono K, Tanaka T, Tsunoda T et al. Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res 2000 60 : 5007 11.
11. Mok SC, Chao J, Skates S et al. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst 2001 93 : 1458 64.
12. Welsh JB, Zarrinkar PP, Sapinoso LM et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci U S A 2001 98 : 1176 81.
13. Tonin PN, Hudson TJ, Rodier F et al. Microarray analysis of gene expression mirrors the biology of an ovarian cancer model. Oncogene 2001 20 : 6617 26.
14. Bayani J, Brenton JD, Macgregor PF et al. Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization, and expression microarrays. Cancer Res 2002 62 : 3466 76.
15. Zhang XY, Li XP, Lai J, Feng J. Screening for ovarian cancer-associated genes with cDNA microarrays in Chinese Ai Zheng 2003 22 : 943 7.
16. Donninger H, Bonome T, Radonovich M et al. Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene 2004 23 : 8065 77.
17. Lancaster JM, Dressman HK, Whitaker RS et al. Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Investig 2004 11 : 51 9.
18. Santin AD, Zhan F, Bellone S et al. Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling. Br J Cancer 2004 90 : 1814 24.
19. Zhang X, Feng J, Cheng Y et al. Characterization of differentially expressed genes in ovarian cancer by cDNA microarrays. Int J Gynecol Cancer 2005 15 : 50 7.
20. Le Page C, Ouellet V, Madore J et al. Gene expression profiling of primary cultures of ovarian epithelial cells identifies novel molecular classifiers of ovarian cancer. Br J Cancer 2006 94 : 436 45.
21. Bignotti E, Tassi RA, Calza S et al. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. Gynecol Oncol 2006 103 : 405 16.
22. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM et al. Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clin Cancer Res 2004 10 : 4427 36.
23. Mougeot JL, Bahrani-Mostafavi Z, Vachris JC et al. Gene expression profiling of ovarian tissues for determination of molecular pathways reflective of tumorigenesis. J Mol Biol 2006 358 : 310 29.
24. Moreno-Bueno G, Sanchez-Estevez C, Cassia R et al. Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res 2003 63 : 5697 702.
25. Zheng M, Simon R, Kononen J, Sauter G, Mihatsch MJ, Moch H. Analysis of gene expression profiles among 3 epithelial ovarian tumor subtypes using cDNA and tissue microarrays in Chinese Ai Zheng 2004 23 : 771 6.
26. Sugimura M, Sagae S, Ishioka S, Nishioka Y, Tsukada K, Kudo R. Mechanisms of paclitaxel-induced apoptosis in an ovarian cancer cell line and its paclitaxel-resistant clone. Oncology 2004 66 : 53 61.
27. Lamendola DE, Duan Z, Yusuf RZ, Seiden MV. Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line. Cancer Res 2003 63 : 2200 5.
28. Selvanayagam ZE, Cheung TH, Wei N et al. Prediction of chemotherapeutic response in ovarian cancer with DNA microarray expression profiling. Cancer Genet Cytogenet 2004 154 : 63 6.
29. Macleod K, Mullen P, Sewell J et al. Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. Cancer Res 2005 65 : 6789 800.
30. Samimi G, Manorek G, Castel R et al. cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistance. Cancer Chemother Pharmacol 2005 55 : 1 11.
31. Bild AH, Yao G, Chang JT et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006 439 : 353 7.
32. Cheng TC, Manorek G, Samimi G, Lin X, Berry CC, Howell SB. Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol 2006 58 : 384 95.
33. Xu S, Mou H, Lu G et al. Gene expression profile differences in high and low metastatic human ovarian cancer cell lines by gene chip. Chin Med J (Engl) 2002 115 : 36 41.
34. Adib TR, Henderson S, Perrett C et al. Predicting biomarkers for ovarian cancer using gene-expression microarrays. Br J Cancer 2004 90 : 686 92.
35. De Cecco L, Marchionni L, Gariboldi M et al. Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2. Oncogene 2004 23 : 8171 83.
36. Ouellet V, Provencher DM, Maugard CM et al. Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling. Oncogene 2005 24 : 4672 87.
37. Motamed-Khorasani A, Jurisica I, Letarte M et al. Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression. Oncogene 2007 26 : 198 214.
38. Bani MR, Nicoletti MI, Alkharouf NW et al. Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. Mol Cancer Ther 2004 3 : 111 21.
39. Wang K, Gan L, Jeffery E et al. Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. Gene 1999 229 : 101 8.
40. Pyle-Chenault RA, Stolk JA, Molesh DA et al. VSGP/F-spondin: a new ovarian cancer marker. Tumour Biol 2005 26 : 245 57.
41. Varma R, Hector S, Greco WR et al. Platinum drug effects on the expression of genes in the polyamine pathway: time-course and concentration-effect analysis based on Affymetrix gene expression profiling of A2780 ovarian carcinoma cells. Cancer Chemother Pharmacol 2007 59 : 711 23.
42. Davidson B, Zhang Z, Kleinberg L et al. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. Clin Cancer Res 2006 12 : 5944 50.
43. Lancaster JM, Dressman HK, Clarke JP et al. Identification of genes associated with ovarian cancer metastasis using microarray expression analysis. Int J Gynecol Cancer 2006 16 : 1733 45.
44. Fossey SC, Kuroda S, Price JA, Pendleton JK, Freedman BI, Bowden DW. Identification and characterization of PRKCBP1, a candidate RACK-like protein. Mamm Genome 2000 11 : 919 25.
45. Koivunen J, Aaltonen V, Peltonen J. Protein kinase C (PKC) family in cancer progression. Cancer Lett 2006 235 : 1 10.
46. Ho A, Sudhof TC. Binding of F-spondin to amyloid-beta precursor protein: a candidate amyloid-beta precursor protein ligand that modulates amyloid-beta precursor protein cleavage. Proc Natl Acad Sci U S A 2004 101 : 2548 53.
47. Tzarfati-Majar V, Burstyn-Cohen T, Klar A. F-spondin is a contact-repellent molecule for embryonic motor neurons. Proc Natl Acad Sci U S A 2001 98 : 4722 7.
48. Miyamoto K, Morishita Y, Yamazaki M et al. Isolation and characterization of vascular smooth muscle cell growth promoting factor from bovine ovarian follicular fluid and its cDNA cloning from bovine and human ovary. Arch Biochem Biophys 2001 390 : 93 100.
49. Terai Y, Abe M, Miyamoto K et al. Vascular smooth muscle cell growth-promoting factor/F-spondin inhibits angiogenesis via the blockade of integrin alphavbeta3 on vascular endothelial cells. J Cell Physiol 2001 188 : 394 402.
50. Winter MJ, Nagtegaal ID, van Krieken JH, Litvinov SV. The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. Am J Pathol 2003 163 : 2139 48.
51. Calabrese G, Crescenzi C, Morizio E, Palka G, Guerra E, Alberti S. Assignment of TACSTD1 (alias TROP1, M4S1) to human chromosome 2p21 and refinement of mapping of TACSTD2 (alias TROP2, M1S1) to human chromosome 1p32 by in situ hybridization. Cytogenet Cell Genet 2001 92 : 164 5.
52. Balzar M, Bakker HAM, Briaire-de Bruijn IH, Fleuren GJ, Warnaar SO, Litvinov SV. Cytoplasmic tail of the intercellular adhesion function of the epithelial adhesion molecule (Ep-CAM). Mol Cell Biol 1998 18 : 4833 43.
53. Linnenbach AJ, Seng BA, Wu S et al. Retroposition in a family of carcinoma-associated antigen genes. Mol Cell Biol 1993 13 : 1507 15.
54. Litvinov SV, van Driel W, Van Rhijn CM et al. Expression of Ep-CAM in cervical squamous epithelia correlates with an increased proliferation and the disappearance of markers for terminal differentiation. Am J Pathol 1996 148 : 865 75.
55. Momburg F, Moldenhauer G, Haemmerling GJ, Moller P. Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res 1987 47 : 2883 91.
56. Ward BG, Lowe DG, Shepherd JH. Patterns of expression of a tumor associated antigen, defined by the monoclonal antibody HMFG2, in human epithelial ovarian carcinoma. Comparison with expression of the HMFG1, AUA1 and F36/22 antigens. Cancer 1987 60 : 787 93.
57. Cherchi PL, Marras V, Capobianco G et al. Immunohistochemical evaluation of a new epithelial antigen, Ber-EP4, in ovarian cancer: preliminary results. Eur J Gynaecol Oncol 2001 12 : 433 5.
58. Nolan LP, Heatley MK. The value of immunocytochemistry in distinguishing between clear cell carcinoma of the kidney and ovary. Int J Gynecol Pathol 2001 20 : 155 9.
59. Armstrong A, Eck SL. EpCAM: a new therapeutic target for an old cancer antigen. Cancer Biol Ther 2003 2 : 320 6.
60. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004 5 : 292 302.
61. Suijkerbuijk RF, Gebbink MF, Moolenaar WH, Geurts van Kessel A. Fine mapping of the human receptor-like protein tyrosine phosphatase gene (PTPRM) to 18p11.2 by fluorescence in situ hybridization. Cytogenet Cell Genet 1993 64 : 245 6.
62. Besco J, Popesco MC, Davuluri RV, Frostholm A, Rotter A. Genomic structure and alternative splicing of murine R2B receptor protein tyrosine phosphatases (PTPkappa, mu, rho and PCP-2). BMC Genomics 2004 5 : 14.
63. Reid LE, Brasnett AH, Gilbert CS et al. A single DNA response element can confer inducibility by both alpha- and gamma-interferons. Proc Natl Acad Sci U S A 1989 86 : 840 4.
64. Deblandre GA, Marinx OP, Evans SS et al. Expression cloning of an interferon-inducible 17-kDa membrane protein implicated in the control of cell growth. J Biol Chem 1995 270 : 23860 6.
65. Yang G, Xu Y, Chen X, Hu G. IFITM1 plays an essential role in the antiproliferative action of interferon-gamma. Oncogene 2007 26 : 594 603.
66. Clauss IM, Wathelet MG, Szpirer J et al. Human thymosin-beta 4/6-26 gene is part of a multigene family composed of seven members located on seven different chromosomes. Genomics 1991 9 : 174 80.
67. Safer D, Elzinga M, Nachmias VT. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem 1991 266 : 4029 32.
68. Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 2004 432 : 466 72.
69. Brazil DP, Park J, Hemmings BA. PKB binding proteins. Getting in on the Akt. Cell 2002 111 : 293 303.
70. Ji P, Diederichs S, Wang W et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 2003 22 : 8031 41.
71. Bhandari V, Palfree RG, Bateman A. Isolation and sequence of the granulin precursor cDNA from human bone marrow reveals tandem cysteine-rich granulin domains. Proc Natl Acad Sci U S A 1992 89 : 1715 9.
72. He Z, Bateman A. Progranulin gene expression regulates epithelial cell growth and promotes tumor growth in vivo. Cancer Res 1999 59 : 3222 9.
73. Lu R, Serrero G. Inhibition of PC cell-derived growth factor (PCDGF, epithelin/granulin precursor) expression by antisense PCDGF cDNA transfection inhibits tumorigenicity of the human breast carcinoma cell line MDA-MB-468. Proc Natl Acad Sci U S A 2000 97 : 3993 8.
74. Davidson B, Alejandro E, Florenes VA et al. Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma. Cancer 2004 100 : 2139 47.
75. Jones MB, Spooner M, Kohn EC. The granulin-epithelin precursor: a putative new growth factor for ovarian cancer. Gynecol Oncol 2003 88 : S136 9.
76. Willott E, Balda MS, Fanning AS, Jameson B, Van Itallie C, Anderson JM. The tight junction protein ZO-1 is homologous to the Drosophila discs-large tumor suppressor protein of septate junctions. Proc Natl Acad Sci U S A 1993 90 : 7834 8.
77. Kurrey NK, Amit K, Bapat SA. Snail and Slug are major determinants of ovarian cancer invasiveness at the transcription level. Gynecol Oncol 2005 97 : 155 65.
78. Olivier RI, van Beurden M, van' T Veer LJ. The role of gene expression profiling in the clinical management of ovarian cancer. Eur J Cancer 2006 42 : 2930 8.
79. Shi L, Tong W, Goodsaid F et al. QA/QC: challenges and pitfalls facing the microarray community and regulatory agencies. Expert Rev Mol Diagn 2004 4 : 761 77.
80. Tan PK, Downey TJ, Spitznagel EL Jr. et al. Evaluation of gene expression measurements from commercial microarray platforms. Nucleic Acids Res 2003 31 : 5676 84.